NewAmsterdam Pharma Company N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands
January 26, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: Cindy Polynice
Joe McCann
| Re: | NewAmsterdam Pharma Company N.V. | |
Amendment No. 1 to Registration Statement on Form F-1 Filed January 17, 2023 | ||
| File No. 333-268888 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on January 30, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.
We respectfully request that we be notified of such effectiveness by a telephone call to Kerry S. Burke of Covington & Burling LLP at (202) 662-5297 and that such effectiveness also be confirmed in writing.
| Respectfully, | ||
| NewAmsterdam Pharma Company N.V. | ||
| By: | /s/ Michael Davidson | |
Name: Michael Davidson Title: Chief Executive Officer and Executive Director | ||
cc: Kerry S. Burke, Covington & Burling LLP
